Introduction
The TAL1 (or SCL) gene was originally identi®ed from its involvement by a recurrent chromosomal translocation in patients with T-cell acute lymphoblastic leukemia (T-ALL) (Begley et al., 1989a; Chen et al., 1990; Finger et al., 1989) . Interstitial deletions that fuse TAL1 coding sequences to the promoter of an upstream gene, SIL (for SCL interrupting locus), were found subsequently to occur with greater frequency than translocations (Aplan et al., 1990; Bernard et al., 1990; Brown et al., 1990) . In still other patients, the gene may be activated in the apparent absence of chromosomal rearrangement . Misexpression of TAL1 by one of these mechanisms represents the most frequent gain-offunction mutation in T-ALL .
TAL1 belongs to the basic helix ± loop ± helix (bHLH) class of transcription factors recognized to regulate myogenic (Molkentin and Olson, 1996) , lymphoid (Bain and Murre, 1998) , neural (DamblyChaudiere and Vervoort, 1998) , and pancreatic (Sander and German, 1997) dierentiation during development. Like the other tissue-restricted members of this family, TAL1 binds DNA as a heterodimer with the products of more widely expressed bHLH genes, including E2A and HEB (Hsu et al., 1991 , collectively referred to as E proteins. These complexes recognize a hexanucleotide sequence CANNTG termed the E box and generally act as positive regulators of transcription (Hsu et al., 1994c; Voronova and Lee, 1994) .
The TAL1 locus encodes at least two protein products. In addition to a full-length protein (pp47 TAL1 ), which has been detected in essentially all cells that transcribe the gene (Cheng et al., 1993; Hsu et al., 1994b) , an amino-terminally truncated protein (pp24 TAL1 ) generated through alternative splicing has been observed in human and murine leukemia cell lines (Cheng et al., 1993; Hsu et al., 1994b) and Friend virus-induced proerythroblasts (Prasad et al., 1995) . This shorter isoform is also the sole TAL1 species expressed in leukemias with the rare SIL-TAL1 d 3 deletion (Bash et al., 1993) . Both proteins contain the bHLH domain and bind to E box sequences (Hsu et al., 1991 (Hsu et al., , 1994a .
The frequent association between activating mutations of this gene and T-ALL suggested that TAL1 misexpression is important in leukemogenesis. Direct evidence for this has come from studies in mice involving enforced expression of a TAL1 transgene targeted to the thymus Kelliher et al., 1996) , although other genetic lesions in the malignant T-cell likely cooperate in this process (Rabbitts, 1998) .
TAL1 also appears to control hematopoietic speci®cation in embryogenesis. TAL1 transcripts and protein have been detected in a number of hematopoietic, as well as certain nonhematopoietic, cell types (Begley et al., 1989b; Green et al., 1991 Green et al., , 1992 Hwang et al., 1993; Kallianpur et al., 1994; Mouthon et al., 1993; Pulford et al., 1995; Visvader et al., 1991) , and its expression in embryonic development pre®gures and parallels sites of blood formation (Kallianpur et al., 1994) . Further, mouse embryos homozygous for a targeted mutation in Tal1 died in midgestation with the complete absence of yolk sac blood cells (Robb et al., 1995; Shivdasani et al., 1995) . Studies evaluating the ability of Tal17/7 embryonic stem cells to contribute to dierent tissues in chimeric mice found that the gene is also required postnatally for the generation of all hematopoietic cell types (Porcher et al., 1996; Robb et al., 1996) .
Considerable data support a speci®c role for TAL1 in erythroid dierentiation. Tal1 expression was found to increase signi®cantly in murine erythroleukemia (MEL) cell lines stimulated to dierentiate with chemical inducers (Aplan et al., 1992; Green et al., 1991) , while expression of Tal1 antisense RNA inhibited their dierentiation (Aplan et al., 1992) . Further, expression of a full length TAL1 cDNA potentiated erythroid dierentiation of a human leukemia cell line (Hoang et al., 1996) and increased erythroid colony formation by normal human bone marrow cells (Elwood et al., 1998) . In contrast, treatment of human hematopoietic progenitors with a TAL1 antisense oligonucleotide led to a reduction in the number of erythroid colonies (Condorelli et al., 1995) . Finally, two growth factors important in erythropoiesis, erythropoietin and stem cell factor, were both found to induce TAL1 expression (Miller et al., 1994; Prasad et al., 1995) .
The widely expressed nuclear proteins p300 and closely related CREB-binding protein (CBP) also act to promote dierentiation in a number of cell types. They have a recognized function as transcriptional coactivators for diverse families of transcription factors, including the nuclear steroid receptors (Chakravarti et al., 1996; Hanstein et al., 1996; Kamei et al., 1996; Yao et al., 1996) , and bHLH Mutoh et al., 1998; Qiu et al., 1998; Sartorelli et al., 1997; Yuan et al., 1996) , leucine zipper (Bannister and Kouzarides, 1995; Bannister et al., 1995; Chrivia et al., 1993; Mink et al., 1997) , and zinc ®nger (Blobel et al., 1998; Lee et al., 1995) proteins. Acting as transcriptional adaptors, they link sequence-speci®c DNA-binding proteins to components of the basal transcriptional machinery (Abraham et al., 1993; Kee et al., 1996; Nakajima et al., 1997) and to proteins with histone acetyltransferase activity (Yang et al., 1996) . Acetylation of core histones in turn induces a localized disruption in nucleosome structure, which facilitates access of transcription factors to DNA (reviewed in Shikama et al., 1997) . The importance of p300/CBP has been demonstrated directly for skeletal muscle dierentiation through antibody microinjection, enforced expression, and use of adenovirus protein E1A to inhibit their function (Caruso et al., 1993; Eckner et al., 1996; Puri et al., 1997a) .
Although the eect of E1A on myogenic differentiation may involve other proteins in addition to p300/ CBP (Puri et al., 1997b; Sandmoller et al., 1996) , its inhibition of murine erythroleukemia (MEL) cell dierentiation (Blobel et al., 1998) suggests these coactivators may also function in terminal erythroid dierentiation. Given the apparent involvement of TAL1 and p300/CBP in erythroid dierentiation and the ability of these coactivators to enhance the transcriptional activity of other lineage-restricted HLH proteins, we investigated whether p300 also interacts with TAL1. Our studies show that recruitment of p300 positively regulates TAL1-directed gene expression and that their interaction in MEL cells is dependent upon cellular dierentiation.
Results

Tal1 and p300 interact in vivo
To investigate whether endogenously expressed Tal1 and p300 interact, a coupled immunoprecipitation/ immunoblot assay was applied to extracts from a MEL cell line induced to dierentiate with dimethylsulfoxide (DMSO). p300 was speci®cally detected in immune precipitates from DMSO-induced MEL cells selected with an antibody to either p300 or Tal1 but not with Tal1 preimmune immunoglobulin ( Figure  1a ). Time course analysis showed, further, that p300 could be coimmunoprecipitated with Tal1 in extracts from cells treated with DMSO for 3 and 5 days (Figure 1b) , paralleling the increase in Tal1 and bglobin gene expression seen with the dierentiation of these cells. This interaction did not persist to day 7 of culture, however. These results indicate that Tal1 and p300 can speci®cally interact in vivo and that their interaction in erythroleukemia cells is dierentiationdependent.
Tal1 and p300 contribute to a common DNA-binding complex Having determined that Tal1 and p300 can interact in vivo, we sought to determine whether they do so in binding to DNA. To that end, electrophoretic mobility shift assays (EMSA) were carried out using extracts from NIH3T3 cells transfected with Tal1 and p300 expression vectors and from Tal1-expressing MEL cells. Although its natural targets have yet to be identi®ed, a preferred DNA-binding sequence was determined for TAL1/E2A heterodimers (Hsu et al., 1994a) that was capable of binding endogenously expressed TAL1 heterodimers (Hsu et al., 1994a) and of directing the transcription of a linked reporter gene (Hsu et al., 1994c) . Using this preferred TAL1/E2A binding site as probe, a highly retarded protein-DNA complex was identi®ed with extracts from both transfected NIH3T3 cells (not shown) and DMSOinduced MEL cells (Figure 2 ). This complex contained both Tal1 and p300, as evidenced by its disruption with polyclonal antibody to Tal1 (Kallianpur et al., 1994; Prasad et al., 1995) and a monoclonal antibody to p300 (RW128) but not an unrelated antibody or Tal1 preimmune immunoglobulin. In accord with the coimmunoprecipitation assays, the ability of MEL extracts to form this DNA-binding complex was dependent on culturing these cells with DMSO. The results of these studies thus indicate the potential for Tal1 and p300 to p300 and TAL1 transcriptional activity S Huang et al contribute to a common DNA-binding complex on an E box element.
Tal1 and p300 interact in vitro
To determine whether Tal1 and p300 were capable of interacting in vitro and to better de®ne the regions involved, pull-down assays were performed using radiolabeled p300 and a glutathione S-transferase (GST) fusion protein containing the complete Tal1 coding region (GST-Tal1 ). Reciprocal studies were also carried out using 35 
S-labeled pp24
Tal1 and a series of GST-p300 fusion proteins. It was found that fulllength p300 could interact with glutathione-Sepharose beads prebound with a fusion protein containing the Tal1 coding sequences but not with beads adsorbed with GST ( Figure 3a) . Further, using radiolabeled pp24 Tal1 and the GST-p300 fusion proteins prebound to beads, the C/H1 domain of p300 was capable by itself in mediating p300-Tal1 interaction in vitro (Figure 3b ). The results of solution binding studies thus demonstrate the ability of both isoforms of TAL1 to interact with p300 in vitro and suggest the p300 C/H1 domain is important for this interaction.
p300 augments transcription stimulated by Tal1-E12 heterodimers
We next sought to determine the eect of p300 on TAL1 transcriptional activity using a model promoter containing multiple copies of the same TAL1/E2A binding site (Hsu et al., 1994a) employed in gel mobility shift assays above. While transactivation was considerably higher with E12 alone, similar to what had been previously reported (Hsu et al., 1994c) , cotransfection of Tal1 and E12 expression vectors led to signi®cant activation of a luciferase reporter gene ( Figure 4 ). Transfection of p300 or a deletion construct lacking the E1A-interacting domain, p300dl10, was found to further increase luciferase gene expression in both Tal1-and E12-transfected HeLa ( Figure 4 ) and NIH3T3 cells (not shown). In addition, p300dl10 was more active than wild-type p300, as also observed for JunB, c-Jun, and BETA-2 (Lee et al., 1996; Qiu et al., As indicated in the key above ®gure, extracts were subjected to immunoprecipitation with an anti-p300 monoclonal antibody (RW128), polyclonal anti-Tal1 antibody, or Tal1 preimmune immunoglobulin, the resulting immune precipitates were then electrotransferred to a polyvinylidene di¯uoride membrane, and the presence of p300 (marked with arrow) was detected by immunoblot analysis with the anti-p300 monoclonal antibody RW128. The exposure time was signi®cantly shorter for chemiluminescent detection of immunoprecipitated p300 in immune precipitates selected with the anti-p300 antibody (®rst lane) than with anti-Tal1 antibody (third lane). (b) Time course analysis of extracts from MEL cells incubated for the indicated times with 1.8% DMSO. Extracts were subjected to immunoprecipitation with an anti-p300 monoclonal antibody (RW128), polyclonal anti-Tal1 antibody, or Tal1 preimmune immunoglobulin, the resulting immune precipitates were electrotransferred to a polyvinylidene di¯uoride membrane, and the presence of p300 (marked with arrowhead) was detected by immunoblot analysis with the anti-p300 antibody Figure 2 Presence of cellular expressed p300 and Tal1 in a common DNA-binding complex. EMSA was carried out with extracts from MEL cells incubated with 1.8% DMSO for 5 days. The preferred TAL1/E2A E box element was used as probe. The complex marked with the arrowhead was supershifted such that it was unable to enter the gel when extracts were preincubated with polyclonal antibody to Tal1 (anti-Tal1) or a monoclonal antibody to p300 (RW128) (anti-p300) but not with a monoclonal antibody to a human c-Myc epitope (9E10) (anti-Myc epitope) or Tal1 preimmune immunoglobulin (Tal1 preimmune) p300 and TAL1 transcriptional activity S Huang et al 1998). While modest from a quantitative standpoint, the magnitude of p300-stimulated coactivation was comparable to that described for BETA-2 (Mutoh et al., 1998) , Smad3 (Janknecht et al., 1998) , and AML1 (Kitabayashi et al., 1998) . Finally, no eect of p300 was seen in cells transfected with the reporter plasmid alone (Figure 4 ). These results indicate that p300 can augment transcription by Tal1/E12 heterodimers from a promoter containing E box sites.
Identi®cation of Tal1 and p300 sequences required for p300-stimulated transactivation
To delineate the sequences required for p300-stimulated transactivation, the entire Tal1 coding region was ®rst fused in-frame with the DNA-binding domain of GAL4 (GAL4 ), and the resulting GAL4-Tal1 fusion was cotransfected with a GAL4-responsive chloramphenicol acetyltransferase (CAT) gene, with and without the p300 expression plasmid pCMVbp300 (Eckner et al., 1994) , into NIH3T3 cells. Reporter gene expression was signi®cantly stimulated by p300, with over ninefold higher CAT activity noted in extracts from cells transfected with both GAL4-Tal1 fusion and p300 expression vectors relative to those transfected with the GAL4-Tal1 fusion alone ( Figure  5a ). As observed for the E box reporter construct, p300dl10 exhibited even greater activity than p300 (not shown).
To map the speci®c Tal1 sequences important for p300-stimulated transactivation, fusion cDNAs containing dierent segments of the Tal1 coding region linked to the GAL4 DNA-binding domain were prepared and transfected with the GAL4-responsive CAT reporter, with and without plasmid pCMVb300, into NIH3T3 cells. A putative transcriptional activation domain localized amino-terminal to bHLH sequences (SaÂ nchez-GarcõÂ a and Rabbitts, 1994; Wadman et al., 1994b ) was found to be dispensable for this activity, as the magnitude of p300-dependent transactivation was similar with a fusion lacking this region to one containing the complete Tal1 coding region (Figure 5b) . Indeed, truncation of sequences aminoterminal to the bHLH domain was associated with an increase in p300-stimulated reporter gene expression. Finally, a GAL4 fusion containing Tal1 sequences limited to the bHLH domain (amino acids 185 ± 240) was capable of supporting p300-stimulated transactivation. No signi®cant change in CAT activity was noted S-labeled full-length p300 was incubated in solution with a GST-Tal1 fusion protein (GST-Tal1 1-330 ) or GST adsorbed on glutathione-Sepharose beads. Bound protein was eluted from beads and quantitated bȳ uorography following SDS ± PAGE. An amount of in vitro translated p300 protein corresponding to one-tenth that added to reactions is shown as input. (b) 35 S-labeled p24
Tal1 was incubated in solution with the indicated GST-p300 fusion proteins or GST adsorbed on glutathione-Sepharose beads. Bound protein was eluted from beads and quantitated by¯urography following SDS ± PAGE. An amount of in vitro translated Tal1 protein corresponding to one-tenth that added to reactions is shown as input Figure 4 Eect of p300 on transactivation by Tal1-E12 heterodimers. HeLa cells were transiently transfected with reporter E1bLuciferase-E6 (1.0 mg) and expression vectors (2.5 mg) for E12, E12 and Tal1, or neither, with or without expression vectors (1.25 mg) for p300 (shaded bars) or p300dl10 (®lled bars). Luciferase activity was determined 48 h after transfection and corrected for variation in transfection eciency by cotransfection with plasmid pRSV-CAT and measurement of CAT activity in extracts. Plotted is luciferase activity for the indicated conditions relative to that obtained with reporter alone. Values represent means+s.e.m. from three independent transfections. Identical results were also obtained with NIH3T3 cells (not shown). *P=0.01; **P=0.002 p300 and TAL1 transcriptional activity S Huang et al when the p300 expression vector was transfected either with the reporter plasmid alone or the reporter plasmid with a vector expressing only GAL4 DNA-binding sequences, indicating a requirement for Tal1 coding sequences for p300-stimulated transactivation. p300 also had no eect grossly on GAL4-Tal1 DNAbinding activities (Figure 6 ), excluding the possibility of p300 stimulating reporter activity through an eect on fusion protein expression. These results indicate that the bHLH domain of Tal1 is sucient for p300-dependent coactivation.
To identify the region(s) of p300 required for stimulation of Tal1-directed gene expression, NIH 3T3 cells were transfected with the GAL4-Tal1 cDNA together with expression vectors encoding the full-length p300 protein, its amino-terminal 1257 amino acids (Np300), or amino acids 871 ± 2378 (Cp300). Each of these p300 constructs contains at least one of the two activation domains identi®ed in the molecule (Yuan et al., 1996) and was able to enhance MyoDdependent transactivation (Sartorelli et al., 1997) . Immunoblot analysis also showed that the amino terminal deletion mutant Cp300 was expressed at similar levels to the full-length protein in transfected NIH3T3 cells (not shown). Deletion of the aminoterminal 870 amino acids of p300 was found to completely abrogate its ability to augment Tal1-directed transcription (Figure 7 ), indicating this region contains sequences required for p300-dependent coactivation. In addition, a fusion made between amino acids 1 ± 1259 of p300 and the herpesvirus VP16 activation domain was capable of stimulating Tal1-directed transcription, while the activity of a similar VP16 fusion containing amino acids 605 ± 1259 was severely reduced (not shown). These ®ndings indicate the importance of the most amino-terminal 605 amino acids of p300 for coactivation of Tal1 transactivating activity. This region includes the C/H1 domain found above to be sucient for Tal1-p300 interaction in solution (Figure 3) .
Discussion
Our studies demonstrate that the TAL1 oncoprotein can associate with the transcriptional coactivator p300 in vivo and in vitro. We show that p300 enhances Tal1-directed gene expression and that the association of these two proteins in erythroleukemia cells is dependent on cellular dierentiation. Both isoforms Figure 5 Eect of p300 on transactivation by GAL4-Tal1 fusions. Vectors encoding the DNA-binding domain and the indicated sequences of Tal1 (1.0 mg) were transfected with and without an expression vector for p300 (10 mg) and its eect determined on expression of a cotransfected GAL4-responsive CAT reporter gene (1.0 mg). Plotted is the CAT activity for the indicated GAL4 fusion, with and without cotransfected p300, relative to that obtained with GAL4 1-147 (mean+s.e.m.). Data were corrected for variation in transfection eciency through cotransfection of an SV40 promoter-driven luciferase gene (pSV2-luciferase) (1.0 mg) and measurement of luciferase activity in extracts p300 and TAL1 transcriptional activity S Huang et al of TAL1 observed in cells were found to interact with p300, and mapping studies identi®ed the aminoterminal half of p300 and the bHLH domain of Tal1 as important for this activity. p300 can interact with transcription factors through either their transcriptional activation domains (Sartorelli et al., 1997; Sato et al., 1997) or their DNA-binding and dimerization domains Mutoh et al., 1998) . Although TAL1 has been reported to possess a weak activation domain (SaÂ nchez-GarcõÂ a and Rabbitts, 1994; Wadman et al., 1994b) , deletion analysis indicated that this region was dispensable for both Tal1-p300 interaction in solution (Figure 3b ) and p300-stimulated transactivation ( Figure 5 ). TAL1 thus resembles E47 , BETA-2 (Mutoh et al., 1998) , and possibly MyoD in that its bHLH domain can apparently mediate interaction with p300.
In addition to its E protein DNA-binding partners, recent studies have shown that the TAL1-encoded proteins can interact with the products of two genes, LMO1 and LMO2, that are themselves activated by chromosomal translocation in T-ALL (Valge-Archer et al., 1994; Wadman et al., 1994a) . LMO1 and LMO2 contain tandem copies of a protein interaction motif termed the LIM domain and have each been shown to cooperate with TAL1 in inducing thymic neoplasms in bitransgenic mice (Aplan et al., 1997; Larson et al., 1996) . LMO2 has also been identi®ed in DNA-binding complexes in erythroid cells containing TAL1, the zinc ®nger transcription factor GATA-1, and the LIM domain-binding protein Ldb1/NL1 (Wadman et al., 1997) . Recruitment of GATA-1 to such complexes was shown to increase their transcriptional potency and to target them to speci®c sites containing E box and GATA-1 binding elements (Wadman et al., 1997) .
Although not yet investigated for the LIM domain proteins, GATA-1 was found recently to interact directly with CBP (Blobel et al., 1998) and p300 (Boyes et al., 1998) . Thus, since TAL1 and GATA-1 interact with dierent portions of the molecule (Figure 3b and Blobel et al., 1998) , recruitment of p300/CBP could act to stabilize these large ternary complexes.
TAL1 has been reported to act as a positive (Hsu et al., 1994c; Ono et al., 1997) and a negative (Hofmann and Cole, 1996; Hsu et al., 1994c; Park and Sun, 1998) regulator of transcription in transient transfection assays. Depending, conceivably, on the speci®c coregulators with which it interacts, it could function physiologically as either an activator or a repressor. While this issue cannot be resolved until its target genes are identi®ed, the observation that p300 augmented transcription by Tal1 coding sequences corresponding to its two principal protein products, at least in the context of GAL4-Tal1 fusion proteins, may have relevance to their respective actions. Although both isoforms were found to cooperate with LMO1 or LMO2 in inducing T-cell leukemia in transgenic mice (Aplan et al., 1997; Larson et al., 1996) , it was suggested that by virtue of lacking an activation domain, pp24 TAL1 did so as a transdominant negative inhibitor (Aplan et al., 1997) . In contrast, our results predict that both TAL1 gene products could act in association with p300 as positive transcriptional regulators, and, indeed, pp24 TAL1 and pp47 TAL1 were similarly eective at transactivating a reporter gene with LMO1 and LMO2 (Ono et al., 1997) . As only the shorter isoform is made in the subset of leukemia-associated SIL-TAL1 fusions in which the ®rst coding exon of TAL1 is deleted (Bash et al., 1993) , if both proteins have the potential to be transcriptional activators, it does not become necessary to invoke opposing mechanisms by which TAL1 misexpression contributes to the development of a single disorder. Figure 6 Expression of DNA-binding activity by GAL4-Tal1 fusion proteins. Nuclear extracts from NIH 3T3 cells transiently transfected with the indicated GAL4 construct plus p300 expression vector (GAL4 construct+p300) or the GAL4 construct alone (GAL4 construct) were subjected to EMSA using a 32 P-labeled oligonucleotide corresponding to GAL4 binding sequences. Protein-DNA complexes containing GAL4-Tal1 fusion protein (arrows) were speci®cally identi®ed by their ability to be supershifted by antibody to the GAL4 DNA-binding domain (anti-GAL4). Shown are results obtained with GAL4-Tal1 1-330 and GAL4-Tal1 1-144 expressing cells. Similar results were obtained with all other GAL4 fusion proteins (not shown) p300 and TAL1 transcriptional activity S Huang et al p300 and CBP have been implicated in multiple regulatory pathways, particularly those involving cellular dierentiation and growth control (Arany et al., 1995; Bhattacharya et al., 1996; Eckner, , 1997 Goldman et al., 1997; Missero et al., 1995; Shikama et al., 1997) . Recent studies in MEL cells using a conditional form of adenovirus E1A to inhibit p300/ CBP function suggest they may have a speci®c role in terminal erythroid dierentiation (Blobel et al., 1998) . Although widely expressed, the concentration and/or activity of these coregulators appear to be limiting in most cells, thus enabling them to integrate signals from dierent extracellular stimuli (Eckner, 1997) . Since both p300 and Tal1 are expressed in uninduced MEL cells without apparently interacting, Tal1 could be constrained from associating with p300 by another coregulator or interacting protein. Alternatively, either or both proteins may undergo posttranslational modi®cation with dierentiation. In any case, given the importance of both p300 and TAL1 in erythroid dierentiation, the ®nding that their interaction in a MEL cell line was inducer-dependent ( Figure 1b) suggests that, in addition to GATA-1 (Blobel et al., 1998; Boyes et al., 1998) and erythroid KruÈ ppel-like factor (Zhang and Bieker, 1998) , TAL1 is a probable target of p300/CBP action in dierentiating erythroid cells.
Materials and methods
Cell culture and transient transfection
MEL cells (line F4-12B2) (Coppola and Cole, 1986) were cultured in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% fetal bovine serum and induced to dierentiate by addition of 1.8% (v/v) DMSO. Cells in logarithmic growth were collected by low-speed centrifugation and washed once with chilled phosphate-buered saline prior to use. NIH3T3 and HeLa cells were cultured on 100 mm plates in DMEM with 10% calf serum. For transient transfections, 2610 6 log phase NIH3T3 or HeLa cells were cultured overnight and transfected with the indicated plasmids using cationic liposomes (LipofectAMINE reagent; Life Technologies, Gaithersburg, MD, USA). Culture medium was replaced 4 h after transfection and the cells harvested 48 h later. CAT and luciferase assays were performed as described by de Wet et al. (1987) and Nordeen et al. (1987) and the data corrected for transfection eciency by cotransfection with pSV2-luciferase or pRSV-CAT, respectively. Empty expression vector (pCMV4) was included to normalize DNA mass transfected. The amount of plasmid used for each transfection is detailed in the ®gure legends. Each transfection was repeated from three to ten times. The signi®cance of dierences in mean reporter activity was determined with a two-tailed t-test.
Plasmids
Eukaryotic expression vectors containing a full-length p300 cDNA (pCMVbp300) and a deletion mutant lacking amino acids 1679 ± 1812, p300dl10, were provided by David Livingston (Dana Farber Cancer Center, Boston, MA, USA) (Eckner et al., 1994) , and vectors expressing amino acids 1 ± 1257 (Np300) and 871 ± 2378 (Cp300) of p300 have also been described (Lee et al., 1995) . pBluescript-p300 was constructed by subcloning the NotI to HindIII fragment of pCMVbp300 into the corresponding sites of pBluescript SK (Stratagene, La Jolla, CA, USA). pGEM-Np300 was prepared by subcloning the HindIII to Bst1107 I fragment of plasmid pNp300 into vector pGEM-3Zf (Promega, Madison, WI, USA). A cDNA encoding pp24
Tal1 was derived by PCR and described previously (Kallianpur et al., 1994; Prasad et al., 1995) .
pGST-Tal1 1-330 was constructed by fusing a full-length Tal1 cDNA (provided by Glenn Begley, Walter and Eliza Hall Institute, Melbourne, Australia) in-frame with GST sequences in vector pGEX-3X. pGST-C/H1 was described by Bhattacharya et al. (1996) and pGST-p300 and pGSTp300 1572-2370 described by Lee et al. (1995) . A full-length Tal1 cDNA was subcloned in-frame with sequences encoding the DNA-binding domain of GAL4 in expression vector pSG424 (Sadowski and Ptashne, 1989) to ) (1.0 mg) were transfected with and without expression vectors containing full-length (p300), amino-terminal (Np300), or carboxy-terminal (Cp300) p300 sequences (each at 10 mg) and their eect determined on expression of a cotransfected GAL4-responsive CAT reporter gene (1.0 mg). Plotted is the CAT activity for the indicated GAL4 fusion, with and without contransfected p300, relative to that obtained with GAL4 1-147 (mean+s.e.m.). Data were corrected for variation in transfection eciency by cotransfection of an SV40 promoter-driven luciferase gene (pSV2-luciferase) (1.0 mg) and measurement of luciferase activity in extracts p300 and TAL1 transcriptional activity S Huang et al generate pGAL4-Tal1 . A 640 bp amino-terminally truncated Tal1 cDNA described previously (Kallianpur et al., 1994; Prasad et al., 1995) was subcloned into the EcoRI site of pSG424 to generate construct pGAL4-Tal1 , and a series of Tal1 truncation mutants generated with PCR were similarly fused to the DNA-binding domain of GAL4 in pSG424 (Sadowski and Ptashne, 1989) . The primers used in these reactions were 5'-CTCGAATTCATGACGGAGCG-GCCGCCGAG-3' and 5'-CTCTCTAGACGAGCGGCTG-GCTAAGGCTAT-3'; 5'-GCCCGTCGACGCCAGCCGC-TCGCCTCACTA-3' and 5'-CTCTCTAGAGGGCAGCCC-CAGACGCATCA-3'; 5'-GCGCGTCGACGAGTAGTGC-GGCGCATCTTCA-3' and 5'-CTCTCTAGAGGGCAGCC-CCAGACGCATCA-3'; 5'-GCGCGTCGACGAGTAGTG-CGGCGCATCTTCA-3' and 5'-GCGCTCTAGAGGCCAG-GAAATTGATGTACT-3', respectively for constructs GAL4-Tal1 , GAL4-Tal1 , GAL4-Tal1 and GAL4-Tal1 . The E1bLUC-E6 reporter construct contains six copies of the preferred TAL1/E2A-binding motif 5'-AACAGATGGT-3' (Hsu et al., 1994a) linked to an E1b-TATA-luciferase reporter. This construct was generously provided by Richard Baer (Texas Southwestern Medical Center, Dallas, TX, USA) and, except for the reporter, is identical to E1bCAT-E6 (Hsu et al., 1994c) . The (GAL4) 5 E1bCAT reporter contains ®ve GAL4-binding sites upstream of a minimal E1b promoter and CAT gene and was provided by Mark Ptashne (Lillie and Green, 1989) .
Electrophoretic mobility shift assay
Nuclear extracts of NIH3T3 cells were prepared as described previously (Prasad et al., 1995) . Total cellular extracts were prepared from NIH3T3 cells transfected with the indicated plasmids and from DMSO-treated MEL cells using the method of Pagano et al. (1992) . Extracts were stored in aliquots at 7708C until used.
Electrophoretic mobility shift assays of the DNA-binding activity of GAL4 fusion proteins were carried out using a double stranded oligonucleotide containing the GAL4 DNAbinding element 5'-GGCGGAAGACTCTCCTCCG-3'. The oligonucleotide was end-labeled with 32 P using T4 polynucleotide kinase, and nuclear proteins extracted from transfected cells were incubated with radiolabeled probe in a buer containing 25 mM HEPES, pH 7.9, 20 mM MgCl 2 , 250 mM NaCl, 5 mM dithiothreitol (DTT), 9% (v/v) glycerol, 0.5 mM phenylmethylsulfonyl¯uoride, and 0.1 mg/ml of salmon sperm DNA in a total volume of 30 ml. When included, polyclonal antibody to the GAL4 DNA-binding domain (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was added to extracts at room temperature 10 min before initiation of the DNA-binding reactions.
To analyse Tal1 DNA-binding activity, a double-stranded oligonucleotide containing a preferred TAL1/E2A binding site (Hsu et al., 1994a) , 5'-ACCTGAACAGATGGTCGGCT-3', was end-labeled with 32 P and incubated with 20 mg of total cellular protein in 20 mM Tris-HCl, pH 7.8, 50 mM KCl, 20% glycerol, 2 mM DTT, and 3 mg/ml poly(dI-dC) in a total volume of 30 ml. When included, the anti-p300 monoclonal antibody RW128 (Upstate Biotechnology, Lake Placid, NY, USA), anity-puri®ed rabbit antibody to Tal1 (Kallianpur et al., 1994) and paired preimmune immunoglobulin or monoclonal antibody 9E10 to a human c-Myc epitope (Sigma Chemical, St. Louis, MO, USA) were added to extracts at room temperature 20 min before initiation of DNA-binding reactions. Protein-DNA complexes were resolved on 4% nondenaturing polyacrylamide gels in Trisglycine buer. Dried gels were exposed to ®lm and analysed by autoradiography.
In vitro transcription/translation and protein interaction assay
One mg of plasmids pBluescript-p300 (see above), pGEMNp300 (see above), Cp300 (Lee et al., 1995) , or pBluescriptpp24
Tal1 (Kallianpur et al., 1994) was used for in vitro transcription and translation in the presence of [ 35 S]methionine (TnT coupled reticulocyte lysate system; Promega, Madison, WI, USA).
The fusion proteins GST-pp47
Tal1
, GST-p300 C/H1 , GSTp300 , and GST-p300 were expressed in Escherichia coli and puri®ed on glutathione-Sepharose beads according to the manufacturer's instructions (Pharmacia Biotech, Piscataway, NJ, USA). Equivalent amounts of puri®ed GST fusion protein or GST were adsorbed to glutathione-Sepharose beads and incubated with 35 S-labeled p300 or pp24
Tal1 in 20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40, and 0.2 mg/ml bovine serum albumin (BSA) at room temperature for 1 h. The resin was then washed 3 ± 4 times using the same buer without BSA, and bound proteins released by boiling in loading buer were resolved on 7.5% or 10% SDS-polyacrylamide gels. Dried gels were subjected to¯uorography.
Immunoprecipitation and immunoblot analysis
Cellular extracts were prepared by lysing cells in radioimmunopreciptiation buer containing 10 mM Tris-HCl, pH 8.0, 140 mM NaCl, 0.025% NaN 3 , 0.5% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl¯uoride, and 2 mg/ml aprotinin. Lysates were incubated at 48C with protein A-Sepharose 4B (Pharmacia Biotech) and precleared with Tal1 preimmune immunoglobulin for 30 min to prevent nonspeci®c binding. Lysates were then incubated with anti-Tal1 antibody for 1.5 ± 2 h at 48C and immune complexes recovered with protein ASepharose 4B. For immunoblot analysis, immune complexes were boiled in Laemmli buer (Laemmli, 1970) for 3 min, fractionated by SDS-polyacrylamide gel electrophoresis (PAGE) and electrotransferred to polyvinylidene di¯uoride membranes. Blots were blocked for 4 ± 5 h in a buer containing 10 mM Tris, pH 8.0, 150 mM NaCl, 0.05% Tween 20, and 5% nonfat dry milk, incubated with the anti-p300 monoclonal antibody RW128 (Upstate Biotechnology) overnight at 48C, and ®nally incubated with a horseradish peroxidase-conjugated secondary antibody for 3 h at 48C. Proteins were visualized by enhanced chemiluminescence (Pierce, Rockford, IL, USA).
Abbreviations T-ALL, T-cell acute lymphoblastic leukemia; bHLH, basic region helix ± loop ± helix; DMSO, dimethylsulfoxide; CBP, CREB-binding protein; CAT, chloramphenicol acetyltransferase; PAGE, polyacrylamide gel electrophoresis; EMSA, electrophoretic mobility shift assay; DTT, dithiothreitol; GST, glutathione S-transferase; BSA, bovine serum albumin.
